Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?
Gastroenterology Report · 22.12.2023 · 12
DOI: 10.1093/gastro/goae024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gastroenterology Report, online erschienen am 11.04.2024. Verfasst von Jimmy Che-To Lai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: General Research Fund—Research Grant Council.
Abstract (Originalsprache)
Liver fibrosis is the common pathway from various chronic liver diseases and its progression leads to cirrhosis which carries a significant risk for the development of portal hypertension-related complications and hepatocellular carcinoma. It is crucial to identify and halt the worsening of liver fibrosis given its important prognostic implication. Liver biopsy is the gold standard for assessing the degree of liver fibrosis but is limited due to its invasiveness and impracticality for serial monitoring. Many noninvasive tests have been developed over the years trying to assess liver fibrosis in a practical and accurate way. The tests are mainly laboratory- or imaging-based, or in combination. Laboratory-based tests can be derived from simply routine blood tests to patented laboratory parameters. Imaging modalities include ultrasound and magnetic resonance elastography, in which vibration-controlled transient elastography is the most widely validated and adopted whereas magnetic resonance elastography has been proven the most accurate liver fibrosis assessment tool. Nonetheless, noninvasive tests do not always apply to all liver diseases, nor does a common cut-off value of a test mean the same degree of liver fibrosis in different scenarios. In this review, we discuss the diagnostic and prognostic performance, as well as the confounders and limitations, of different noninvasive tests on liver fibrosis assessment in various liver diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
- State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Grace Lai-Hung Wong
Förderung
- General Research Fund—Research Grant Council
Zitieren
APA
Lai, J. C., Liang, L. Y., & Wong, G. L. (2023). Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?. Gastroenterology Report, 12. https://doi.org/10.1093/gastro/goae024
Vancouver
Lai JC, Liang LY, Wong GL. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?. Gastroenterology Report. 2023;12. doi:10.1093/gastro/goae024
BibTeX
@article{Lai2023,
author = {Lai, Jimmy Che-To and Liang, Lilian Yan and Wong, Grace Lai-Hung},
title = {Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?},
journal = {Gastroenterology Report},
year = {2023},
volume = {12},
doi = {10.1093/gastro/goae024}
}
EUVIMED